1. The purpose of this Core is to provide a facility for the propagation of xenografts of pediatric solid tumors, for use in all Projects. The standard model will comprise CBA/CaJ mice immune-deprived by a procedure of thymectomy, whole body irradiation and marrow reconstitution. For specific experiments, SCID mice will be used to establish new xenograft lines (glioblastoma) or where growth of tumors in the standard model is not optimal (some osteosarcomas). 2. Coordinate tumor transplantation and make available tumor-bearing mice for biochemical and pharmacokinetic studies as required. 3. Undertake drug evaluation studies using standardized protocols. Data will be accessed directly into a microcomputer, and information distributed on a regular basis to individual project leaders and to the Biostatistics Core for analysis. 4. Establish models of minimal residual disease for evaluating both cytotoxic and novel approaches to tumor ieradication (e.g., gene therapy). 5. Evaluate orthotopic implantation as a secondary screen for drug evaluation. 6. Continue to derive models of tumors resistant to camptothecin inhibitors of topoisomerase I. 7. Maintain and characterize human xenografts, and maintain frozen stocks. 8. Provide services (e.g. blood collection, 1 to 5 day infusions in mice). A program """"""""working committee"""""""" will serve to prioritize the order for evaluating new agents and strategies derived from individual projects, and for allocating resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA023099-21
Application #
6101972
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
21
Fiscal Year
1999
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Dowless, Michele; Lowery, Caitlin D; Shackleford, Terry et al. (2018) Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling. Clin Cancer Res 24:6028-6039
Bishop, Michael W; Advani, Shailesh M; Villarroel, Milena et al. (2018) Health-Related Quality of Life and Survival Outcomes of Pediatric Patients With Nonmetastatic Osteosarcoma Treated in Countries With Different Resources. J Glob Oncol :1-11
Wang, Tingting; Liu, Lingling; Chen, Xuyong et al. (2018) MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Cell Death Dis 9:220
Feng, Helin; Tillman, Heather; Wu, Gang et al. (2018) Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines. Oncotarget 9:27087-27091
Hu, Dongli; Jablonowski, Carolyn; Cheng, Pei-Hsin et al. (2018) KDM5A Regulates a Translational Program that Controls p53 Protein Expression. iScience 9:84-100
Power-Hays, Alexandra; Friedrich, Paola; Fernandez, Gretchen et al. (2017) Delivery of radiation therapy in resource-limited settings: A pilot quality assessment study. Pediatr Blood Cancer 64:
Brennan, Rachel C; Qaddoumi, Ibrahim; Mao, Shenghua et al. (2017) Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. J Clin Oncol 35:72-77
Yu, Peter Y; Gardner, Heather L; Roberts, Ryan et al. (2017) Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One 12:e0181885
Yang, Jun; Milasta, Sandra; Hu, Dongli et al. (2017) Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. Cancer Res 77:4626-4638
Brennan, Rachel C; Qaddoumi, Ibrahim; Billups, Catherine A et al. (2016) Patients with retinoblastoma and chromosome 13q deletions have increased chemotherapy-related toxicities. Pediatr Blood Cancer 63:1954-8

Showing the most recent 10 out of 814 publications